Intellia Shares Climb on Positive Gene-Editing Data

By Matt Grossman

Intellia Therapeutics Inc. shares soared Monday morning after the company reported positive interim data from a Phase 1 clinical study of a gene-editing candidate treatment.

Shares rose 43% in pre-market trading after closing last week at $88.83.

The candidate treatment, NTLA-2001, is being developed for transthyretin amyloidosis. It is the first CRISPR/Ca9-based therapy candidate to be administered via intravenous infusion for precision editing of a human gene, Intellia said.

The treatment is meant to deactivate a gene in liver cells to prevent production of a protein that causes the sometimes-fatal complications of amyloidal.

Dr. John Leonard, Intellia's chief executive, said that the company's data also serve as a promising foundation for treating a variety of other genetic diseases with Intellia's platform.

Intellia is working with Regeneron Pharmaceuticals Inc. to develop NTLA-2001.

Write to Matt Grossman at [e-mail]

(END) Dow Jones Newswires

06-28-21 0708ET